DRUG
Bright Minds Biosciences Inc.
Set alert
- YTD
- -29.55%
- 1 year
- +0.94%
- Open
- 56.78
- Prev close
- 56.69
- Mkt cap
- 542.33M
- Vol
- 95.82K
- Avg vol
- 129.68K
- EPS
- -2.05
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 54.96
- High
- 57.00
- Forward P/E
- 0.00
- Beta
- 1.13
- Short ratio
- 0.70
- Inst. own
- 44.28%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 17, 2010
- 50-d avg
- 40.29
- 200-d avg
- 10.93
- 1y target
- 0.00
Key statistics
- Market cap
- 264.82M
- Enterprise value
- 166.35M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 28.32
- EPS (TTM)
- -0.61
- Beta
- 1.13
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -1.34M
- Total cash
- 6.19M
- Total debt
- 14.02K
- Return on equity
- -51.80%
- Shares outstanding
- 6.08M
- Short % of float
- 3.63%
- 50-day average
- 40.29
- 200-day average
- 10.93
Analyst view
Consensus: none
Next earnings
May 17, 2010
Expected May 17, 2010. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 14, 2024 | Jun 1, 2024 | 0.00 | 0.04 | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | -0.10 | — | — |
| Feb 12, 2024 | Dec 1, 2023 | 0.00 | -0.32 | — | — |
| Dec 29, 2023 | Sep 1, 2023 | 0.00 | -0.30 | — | — |
| May 17, 2010 | Mar 1, 2010 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 25, 2024 | Baird | init | — | Outperform |
About Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- brightmindsbio.com
News
- CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM
- Wolfe Research Initiates Coverage On Bright Minds Biosciences with Outperform Rating, Announces Price Target of $150
- Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
- Bright Minds Biosciences to Present at Upcoming Conferences
- What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?
- Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
- HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target
- BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target
- Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet
- Vistagen Appoints Douglas J. Williamson to its Board of Directors
Your note
Sign in to keep a note on DRUG — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Fryzuk (Jeremy) | Director of Issuer | Acquisition or disposition in the public market | Aug 23, 2022 | 30,000 |
| Kozikowski Alan P | 10% Security Holder of Issuer | Acquisition or disposition in the public market | Dec 29, 2021 | 2,002,500 |
| McDonald (Ian) | Director of Issuer | Acquisition or disposition in the public market | Dec 14, 2021 | 914,900 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Investments, LLC | 2.63% | 182,420 | 7.06M | Sep 29, 2024 |
| National Bank of Canada/FI | 0.07% | 4,959 | 191.86K | Sep 29, 2024 |
| UBS Group AG | 0.05% | 3,407 | 131.82K | Sep 29, 2024 |
| Royal Bank of Canada | 0.01% | 660 | 25.54K | Sep 29, 2024 |
| Aspire Private Capital, LLC | 0.00% | 100 | 3.87K | Sep 29, 2024 |
| Blackrock Inc. | 0.00% | 1 | 38 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.00% | 297 | 11.49K | Oct 30, 2024 |